Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Sep 20;372(9643):1065-72.
doi: 10.1016/S0140-6736(08)61448-8.

Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial

Stanley J Szefler  1 , Herman Mitchell, Christine A Sorkness, Peter J Gergen, George T O'Connor, Wayne J Morgan, Meyer Kattan, Jacqueline A Pongracic, Stephen J Teach, Gordon R Bloomberg, Peyton A Eggleston, Rebecca S Gruchalla, Carolyn M Kercsmar, Andrew H Liu, Jeremy J Wildfire, Matthew D Curry, William W Busse
Affiliations
Randomized Controlled Trial

Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial

Stanley J Szefler et al. Lancet. .

Abstract

Background: Preliminary evidence is equivocal about the role of exhaled nitric oxide (NO) in clinical asthma management. We aimed to assess whether measurement of exhaled NO, as a biomarker of airway inflammation, could increase the effectiveness of asthma treatment, when used as an adjunct to clinical care based on asthma guidelines for inner-city adolescents and young adults.

Methods: We did a randomised, double-blind, parallel-group trial at ten centres in the USA. We screened 780 inner-city patients, aged 12-20 years, who had persistent asthma. All patients completed a run-in period of 3 weeks on a regimen based on standard treatment. 546 eligible participants who adhered to treatment during this run-in period were then randomly assigned to 46 weeks of either standard treatment, based on the guidelines of the National Asthma Education and Prevention Program (NAEPP), or standard treatment modified on the basis of measurements of fraction of exhaled NO. The primary outcome was the number of days with asthma symptoms. We analysed patients on an intention-to-treat basis. This trial is registered with clinicaltrials.gov, number NCT00114413.

Findings: During the 46-week treatment period, the mean number of days with asthma symptoms did not differ between the treatment groups (1.93 [95% CI 1.74 to 2.11] in the NO monitoring group vs 1.89 [1.71 to 2.07] in the control group; difference 0.04 [-0.22 to 0.29], p=0.780). Other symptoms, pulmonary function, and asthma exacerbations did not differ between groups. Patients in the NO monitoring group received higher doses of inhaled corticosteroids (difference 119 mug per day, 95% CI 49 to 189, p=0.001) than controls. Adverse events did not differ between treatment groups (p>0.1 for all adverse events).

Interpretation: Conventional asthma management resulted in good control of symptoms in most participants. The addition of fraction of exhaled NO as an indicator of control of asthma resulted in higher doses of inhaled corticosteroids, without clinically important improvements in symptomatic asthma control.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Consort Diagram
Consort Diagram showing the flow of participants from enrollment to completion of study.
Figure 2
Figure 2. Asthma Outcomes and Medications by Study Visit*
Mean values and 95% confidence intervals for asthma outcomes, pulmonary function and medications burden through the course of the study with maximum symptom days (Panel A), FEV1 % predicted (Panel B), exhaled nitric oxide levels (Panel C), adherence by percent of doses taken (Panel D), inhaled corticosteroid dose in mcg/day (Panel E), and long-acting ß2-agonist therapy in mcg/day (Panel F). The first three weeks constitute the run-in period. * Data for treatment related variables (Panels D,E and F) is presented through the final treatment assessment at week 41, whereas follow-up data panels (Panels A,B and C) continue through week 49, the end of the study period
See this image and copyright information in PMC

Comment in

References

    1. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. Report No.: Publication no. 08-4051.1.
    1. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120:S94–138. - PubMed
    1. Silkoff PE, Carlson M, Bourke T, Katial R, Ogren E, Szefler SJ. The Aerocrine exhaled nitric oxide monitoring system Niox is cleared by the US food and drug administration for monitoring therapy in asthma. J Allergy Clin Immunol. 2004;114(5):1241–56. - PubMed
    1. Massaro AF, Gaston B, Kita D, Fanta C, Stamler JS, Drazen JM. Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med. 1995;152(2):800–3. - PubMed
    1. Stirling RG, Kharitonov SA, Campbell D, et al. Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids. Asthma and Allergy Group. Thorax. 1998;53(12):1030–4. - PMC - PubMed

Publication types

MeSH terms

Associated data